Inicio  /  Cancers  /  Vol: 14 Par: 4 (2022)  /  Artículo
ARTÍCULO
TITULO

Using a 31-Gene Expression Profile Test to Stratify Patients with Stage I?II Cutaneous Melanoma According to Recurrence Risk: Update to a Prospective, Multicenter Study

Sebastian Podlipnik    
Aram Boada    
Jose L. López-Estebaranz    
Manuel M. Martín-González    
Pedro Redondo    
Brian Martin    
Ann P. Quick    
Christine N. Bailey    
Sarah J. Kurley    
Robert W. Cook and Susana Puig    

Resumen

Many people with skin cancer will have their cancer come back. The 31-gene expression profile (31-GEP) test can help predict if a cancer has a low (Class 1) or high (Class 2) chance of returning. This study looked at 86 patients with early skin cancer to see how well the 31-GEP test predicted if their cancer would return. None of the patients with a Class 1 GEP result had their cancer return within 3 years, but one-fourth of patients with a Class 2 result did. This study showed that the 31-GEP test can help predict if a patient?s skin cancer will return. Accurate risk prediction can help doctors make better treatment plans for patients with skin cancer.

PÁGINAS
pp. 0 - 0
REVISTAS SIMILARES

 Artículos similares